BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

17945

543064

SUVENPHAR

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SUVEN PHARMACEUTICALS LTD performance

Today’s low

Today’s high

₹ 1126.50 ₹ 1161.40
₹ 1137.10

52 week low

52 week high

₹ 598.00 ₹ 1360.00
₹ 1137.10

Open Price

₹ 1137.00

Prev. Close

₹ 1136.40

Volume (Shares)

121688.00

Total traded value

₹ 1383.71

Upper Circuit

₹ 1363.60

Lower Circuit

₹ 909.20

info

SUVEN PHARMACEUTICALS LTD Share Price Update

As of the latest trading session, SUVEN PHARMACEUTICALS LTD share price is currently at ₹ 1133.3, which is down by ₹ -3.09 from its previous closing. Today, the stock has fluctuated between ₹ 1126.50 and ₹ 1161.40. Over the past year, SUVEN PHARMACEUTICALS LTD has achieved a return of 72.17 %. In the last month alone, the return has been 5.87 %. Read More...

SUVEN PHARMACEUTICALS LTD fundamentals


  • Market cap (Cr)

    28,849.85

  • P/E Ratio (TTM)

    102.66

  • Beta

    0.63

  • Book Value / share

    86.66

  • Return on equity

    14.31%

  • EPS (TTM)

    11.05

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    86.35

info icon alternate text
  • Market cap (Cr)

    28,642.38

  • P/E Ratio (TTM)

    102.66

  • Beta

    0.61

  • Book Value / share

    86.66

  • Return on equity

    14.31%

  • EPS (TTM)

    11.05

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    86.35

info icon alternate text

SUVEN PHARMACEUTICALS LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 275.39
Operating Expense 175.97
Net Profit 86.35
Net Profit Margin (%) 31.35
Earnings Per Share (EPS) 3.39
EBITDA 130.64
Effective Tax Rate (%) 24.65
Particulars SEP 2024 (Values in Cr)
Revenue 236.06
Operating Expense 148.81
Net Profit 76.33
Net Profit Margin (%) 32.33
Earnings Per Share (EPS) 3.00
EBITDA 114.44
Effective Tax Rate (%) 24.18
Particulars JUN 2024 (Values in Cr)
Revenue 222.09
Operating Expense 152.65
Net Profit 65.07
Net Profit Margin (%) 29.29
Earnings Per Share (EPS) 2.56
EBITDA 100.99
Effective Tax Rate (%) 25.54
Particulars MAR 2024 (Values in Cr)
Revenue 243.52
Operating Expense 189.32
Net Profit 53.43
Net Profit Margin (%) 21.94
Earnings Per Share (EPS) 2.10
EBITDA 89.01
Effective Tax Rate (%) 24.79
Particulars DEC 2023 (Values in Cr)
Revenue 212.82
Operating Expense 157.29
Net Profit 52.36
Net Profit Margin (%) 24.60
Earnings Per Share (EPS) 2.06
EBITDA 83.03
Effective Tax Rate (%) 24.66
Particulars MAR 2024 (Values in Cr)
Revenue 1024.99
Operating Expense 671.31
Net Profit 304.82
Net Profit Margin (%) 29.73
Earnings Per Share (EPS) 11.97
EBITDA 464.99
Effective Tax Rate (%) 25.42
Particulars MAR 2023 (Values in Cr)
Revenue 1330.08
Operating Expense 795.24
Net Profit 432.60
Net Profit Margin (%) 32.52
Earnings Per Share (EPS) 16.99
EBITDA 635.24
Effective Tax Rate (%) 25.33
Particulars MAR 2022 (Values in Cr)
Revenue 1320.22
Operating Expense 785.56
Net Profit 558.10
Net Profit Margin (%) 42.27
Earnings Per Share (EPS) 21.92
EBITDA 767.78
Effective Tax Rate (%) 22.74
Particulars MAR 2021 (Values in Cr)
Revenue 1009.72
Operating Expense 609.97
Net Profit 308.65
Net Profit Margin (%) 30.56
Earnings Per Share (EPS) 12.12
EBITDA 454.76
Effective Tax Rate (%) 25.44
Particulars MAR 2020 (Values in Cr)
Revenue 833.79
Operating Expense 494.31
Net Profit 270.08
Net Profit Margin (%) 32.39
Earnings Per Share (EPS) 21.21
EBITDA 399.76
Effective Tax Rate (%) 24.47
Particulars MAR 2024 (Values in Cr)
Book Value / Share 80.56
ROE % 14.11
ROCE % 18.69
Total Debt to Total Equity 0.04
EBITDA Margin 40.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 68.16
ROE % 25.21
ROCE % 33.22
Total Debt to Total Equity 0.05
EBITDA Margin 46.30
Particulars MAR 2022 (Values in Cr)
Book Value / Share 59.99
ROE % 29.79
ROCE % 40.62
Total Debt to Total Equity 0.09
EBITDA Margin 48.55
Particulars MAR 2021 (Values in Cr)
Book Value / Share 46.38
ROE % 35.78
ROCE % 40.45
Total Debt to Total Equity 0.16
EBITDA Margin 50.61
Particulars MAR 2020 (Values in Cr)
Book Value / Share 66.37
ROE % 44.58
ROCE % 49.77
Total Debt to Total Equity 0.19
EBITDA Margin 54.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 80.76
ROE % 14.31
ROCE % 18.82
Total Debt to Total Equity 0.04
EBITDA Margin 41.10
Particulars MAR 2023 (Values in Cr)
Book Value / Share 68.72
ROE % 26.46
ROCE % 34.28
Total Debt to Total Equity 0.05
EBITDA Margin 47.76
Particulars MAR 2022 (Values in Cr)
Book Value / Share 59.74
ROE % 43.17
ROCE % 51.45
Total Debt to Total Equity 0.09
EBITDA Margin 58.33
Particulars MAR 2021 (Values in Cr)
Book Value / Share 41.84
ROE % 33.40
ROCE % 38.83
Total Debt to Total Equity 0.18
EBITDA Margin 45.29
Particulars MAR 2020 (Values in Cr)
Book Value / Share 61.50
ROE % 39.71
ROCE % 45.81
Total Debt to Total Equity 0.20
EBITDA Margin 48.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 50.49
Total Assets 2254.08
Total Liabilities 2254.08
Total Equity 2050.66
Share Outstanding 254564960
Price to Book Ratio 8.38
Return on Assets (%) 13.32
Return on Capital (%) 14.37
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 68.01
Total Assets 1965.74
Total Liabilities 1965.74
Total Equity 1735.18
Share Outstanding 254564960
Price to Book Ratio 6.88
Return on Assets (%) 20.92
Return on Capital (%) 22.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 47.30
Total Assets 1829.58
Total Liabilities 1829.58
Total Equity 1527.18
Share Outstanding 254564960
Price to Book Ratio 10.34
Return on Assets (%) 24.80
Return on Capital (%) 27.97
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.65
Total Assets 1474.47
Total Liabilities 1474.47
Total Equity 1180.79
Share Outstanding 254564960
Price to Book Ratio 11.84
Return on Assets (%) 24.57
Return on Capital (%) 27.41
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 14.07
Total Assets 1172.81
Total Liabilities 1172.81
Total Equity 844.76
Share Outstanding 127282478
Price to Book Ratio 3.28
Return on Assets (%) 27.02
Return on Capital (%) 30.78
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 21.58
Total Assets 2240.71
Total Liabilities 2240.71
Total Equity 2055.89
Share Outstanding 254564960
Price to Book Ratio 8.38
Return on Assets (%) 13.60
Return on Capital (%) 14.55
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 46.23
Total Assets 1958.33
Total Liabilities 1958.33
Total Equity 1749.38
Share Outstanding 254564960
Price to Book Ratio 6.88
Return on Assets (%) 22.09
Return on Capital (%) 23.79
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 32.95
Total Assets 1804.88
Total Liabilities 1804.88
Total Equity 1520.69
Share Outstanding 254564960
Price to Book Ratio 10.34
Return on Assets (%) 30.92
Return on Capital (%) 34.53
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.56
Total Assets 1358.82
Total Liabilities 1358.82
Total Equity 1065.18
Share Outstanding 254564960
Price to Book Ratio 11.84
Return on Assets (%) 22.71
Return on Capital (%) 25.58
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 13.95
Total Assets 1110.88
Total Liabilities 1110.88
Total Equity 782.82
Share Outstanding 127282478
Price to Book Ratio 3.28
Return on Assets (%) 24.31
Return on Capital (%) 27.9
Particulars MAR 2024 (Values in Cr)
Net Income 405.67
Cash from Operations 468.43
Cash from Investing -362.25
Cash from Financing -13.80
Net change in Cash -17.57
Free Cash Flow 520.22
Particulars MAR 2023 (Values in Cr)
Net Income 559.72
Cash from Operations 602.95
Cash from Investing -195.00
Cash from Financing -241.95
Net change in Cash 20.23
Free Cash Flow 888.86
Particulars MAR 2022 (Values in Cr)
Net Income 667.58
Cash from Operations 514.25
Cash from Investing -136.13
Cash from Financing -156.48
Net change in Cash 37.38
Free Cash Flow 589.44
Particulars MAR 2021 (Values in Cr)
Net Income 467.67
Cash from Operations 491.98
Cash from Investing -311.39
Cash from Financing -75.66
Net change in Cash -4.51
Free Cash Flow 602.82
Particulars MAR 2020 (Values in Cr)
Net Income 404.51
Cash from Operations 493.32
Cash from Investing -413.44
Cash from Financing 7.32
Net change in Cash 0.79
Free Cash Flow 596.39
Particulars MAR 2024 (Values in Cr)
Net Income 408.77
Cash from Operations 479.16
Cash from Investing -381.57
Cash from Financing -13.77
Net change in Cash -24.70
Free Cash Flow 529.48
Particulars MAR 2023 (Values in Cr)
Net Income 579.39
Cash from Operations 638.60
Cash from Investing -236.86
Cash from Financing -243.14
Net change in Cash 12.81
Free Cash Flow 783.21
Particulars MAR 2022 (Values in Cr)
Net Income 722.44
Cash from Operations 421.63
Cash from Investing -90.36
Cash from Financing -156.41
Net change in Cash 23.11
Free Cash Flow 496.82
Particulars MAR 2021 (Values in Cr)
Net Income 413.97
Cash from Operations 438.27
Cash from Investing -257.65
Cash from Financing -75.66
Net change in Cash -4.48
Free Cash Flow 549.11
Particulars MAR 2020 (Values in Cr)
Net Income 357.59
Cash from Operations 445.15
Cash from Investing -366.64
Cash from Financing 8.57
Net change in Cash 0.67
Free Cash Flow 548.22
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

SUVEN PHARMACEUTICALS LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1137.10 0.06 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 1151.70
  • 26 Days 1151.70
  • 10 Days 1157.60
  • 50 Days 1147.00
  • 12 Days 1157.20
  • 100 Days 1140.00
  • 20 Days 1153.80
  • 200 Days 1079.50
1141.43 PIVOT

First Support

1116.97

First Resistance

1160.87

Second Support

1097.53

Second Resistance

1185.33

Third Support

1073.07

Third Resistance

1204.77

RSI

47.88

ADX

10.98

MACD

5.47

Williams % R

-55.07

Commodity Channel Index (CCI)

-1.22

Date

2025-04-30

Week

96712.00

Same Day

61686.00

Month

147337.00

1 Year

0.63

3 Year

0.47

Over 1 Month

5.87%

down

Over 1 Year

72.17%

down

Over 3 Months

9.55%

down

Over 3 Years

24.72%

down

Over 6 Months

-11.00%

down

Over 5 Years

50.29%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

SUVEN PHARMACEUTICALS LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
22.24%
Promoter Holdings
50.1%
FII
11.04%
DII
16.6%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Berhyanda Limited 1.27539592E8 (50.1%) Shareholding of Promoter and Promoter Group
Jasti Property And Equity Holdings Private Limited 2.5192957E7 (9.9%) Public Shareholding
Dsp Regular Savings Fund 1.1192539E7 (4.4%) Public Shareholding
Sbi Life Insurance Co. Ltd 7600965.0 (2.99%) Public Shareholding
Invesco India Contra Fund 4760613.0 (1.87%) Public Shareholding
Goldman Sachs Funds - Goldman Sachs India Equity P 3119539.0 (1.23%) Public Shareholding
Hsbc Midcap Fund 2646511.0 (1.04%) Public Shareholding

News

Left Arrow
Right Arrow

SUVEN PHARMACEUTICALS LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
09 Sep 2022 1.0 Interim 12 Sep 2022 Equity shares
09 Sep 2022 5.0 Special 12 Sep 2022 Equity shares
13 May 2022 1.0 Interim 2 17 May 2022 Equity shares
13 May 2022 1.0 Special 17 May 2022 Equity shares
15 Feb 2022 1.0 Interim 16 Feb 2022 Equity shares
15 Feb 2022 2.0 Special 16 Feb 2022 Equity shares
13 Aug 2021 1.0 Final 17 Aug 2021 Equity shares
17 Feb 2021 1.0 Interim 18 Feb 2021 Equity shares
Ex-Date Ex-Bonus Ratio
28 Sep 2020 25 Sep 2020 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
09 Sep 2022 1.0 Interim 12 Sep 2022 Equity shares
09 Sep 2022 5.0 Special 12 Sep 2022 Equity shares
13 May 2022 1.0 Interim 2 17 May 2022 Equity shares
13 May 2022 1.0 Special 17 May 2022 Equity shares
15 Feb 2022 1.0 Interim 16 Feb 2022 Equity shares
15 Feb 2022 2.0 Special 16 Feb 2022 Equity shares
13 Aug 2021 1.0 Final 17 Aug 2021 Equity shares
17 Feb 2021 1.0 Interim 18 Feb 2021 Equity shares
Ex-Date Ex-Bonus Ratio
28 Sep 2020 25 Sep 2020 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

SUVEN PHARMACEUTICALS LTD Share Price

Suven Pharmaceuticals Limited (SPL) is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors. The Company's comprehensive services encompass- Custom Synthesis, Process R&D,
Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations.

Suven Pharmaceuticals Limited was incorporated on 6 November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company has established core competencies in cyanation and heterocyclic chemistry, covering pyrimidines, quinolones, thiazoles, and imidazoles.

The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS Business Undertaking Division to the Company through the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company.

In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.

The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.

The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21.

During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020.

As on 31 March 2020,the company has one subsidiary and one associate company under its roof.

The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.

The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..

In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.

During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.

Parent organization Indian Private
NSE symbol SUVENPHAR
Founded 2018
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Suven Pharmaceuticals Ltd?

Answer Field

The share price of Suven Pharmaceuticals Ltd for NSE is ₹ 1133.3 and for BSE is ₹ 1125.15.

What is the Market Cap of Suven Pharmaceuticals Ltd?

Answer Field

The market cap of Suven Pharmaceuticals Ltd for NSE is ₹ 2,88,49.85 Cr. and for BSE is ₹ 2,86,42.38 Cr. as of now.

What is the 52 Week High and Low of Suven Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Suven Pharmaceuticals Ltd for NSE is ₹ 1360.00 and ₹ 598.00 and for BSE is ₹ 1359.00 and ₹ 597.00.

How to Buy Suven Pharmaceuticals Ltd share?

Answer Field

You can trade in Suven Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Suven Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 72.17%.

What is the Current Share Price of Suven Pharmaceuticals Ltd?

Answer Field

Suven Pharmaceuticals Ltd share price is for NSE ₹ 1133.3 & for BSE ₹ 1125.15 as on Apr 30 2025 03:29 PM.

What is the Market Cap of Suven Pharmaceuticals Ltd Share?

Answer Field

The market cap of Suven Pharmaceuticals Ltd for NSE ₹ 2,88,49.85 & for BSE ₹ 2,86,42.38 as on Apr 30 2025 03:29 PM.

What is the P/E Ratio of Suven Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Suven Pharmaceuticals Ltd share is 102.66.

What is the PB ratio of Suven Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Suven Pharmaceuticals Ltd share is 86.66.

How to Buy Suven Pharmaceuticals Ltd Share?

Answer Field

You can trade in Suven Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Suven Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Suven Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Suven Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|